Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunogenicity screening in protein drug development.

Ivo Van Walle1, Yannick Gansemans, Paul W H I Parren

  • 1Algonomics NV, Technologiepark 4, 9052 Gent-Zwijnaarde, Belgium. ivo.van.walle@algonomics.com

Expert Opinion on Biological Therapy
|February 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimally invasive 1 mm skin biopsies capture site-specific transcriptomic heterogeneity in vitiligo.

Frontiers in immunology·2026
Same author

Delayed plant genetic responses to forest edge dynamics and their conservation implications.

Conservation biology : the journal of the Society for Conservation Biology·2026
Same author

Reply to the correspondence on 'Development of bispecific antibodies that allow targeted local complement inhibition on rheumatoid arthritis related antigens'.

Annals of the rheumatic diseases·2026
Same author

Differentially expressed miRNAs in the temporal cortex of Alzheimer's disease patients and their association to tau pathology.

Communications biology·2026
Same author

Immunogenicity of a CXCL8-based biopharmaceutical drug candidate in comparison to its wildtype form.

Frontiers in immunology·2026
Same author

Curcumin-based benzothiazepane analogues exhibit selective anti-cancer activity in HCT-116 cells via precipitated particle formation and internalisation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Therapeutic proteins can trigger immune responses by forming antidrug antibodies. Novel in silico methods can now efficiently identify T cell epitopes, reducing the time and cost of assessing immunogenicity during drug development.

Area of Science:

  • Immunology
  • Pharmacology
  • Bioinformatics

Background:

  • Therapeutic proteins often elicit immunogenic responses, leading to antidrug antibodies that can impact drug safety and pharmacokinetics.
  • Assessing protein immunogenicity is crucial during drug development.
  • Traditional methods for identifying T cell epitopes rely on in vitro assays using human blood cells.

Purpose of the Study:

  • To introduce and highlight the utility of in silico methods for identifying T cell epitopes.
  • To demonstrate how in silico approaches can guide and enhance traditional in vitro immunogenicity assessment.
  • To reduce the time and cost associated with evaluating T cell epitopes for therapeutic proteins.

Main Methods:

  • Utilizing in silico computational tools to predict T cell epitopes.

Related Experiment Videos

  • Mapping epitopes across a wide range of human leukocyte antigen (HLA) molecules.
  • Integrating in silico predictions with targeted in vitro assays.

    • Main Results:

    • In silico methods offer a cost-effective way to identify T cell epitopes.
    • These computational approaches enable the analysis of epitopes from diverse genetic backgrounds (HLA molecules).
    • In silico data allows for focused in vitro testing on selected peptides and HLA haplotypes.

    Conclusions:

    • In silico epitope identification is a valuable, emerging tool in therapeutic protein development.
    • Combining in silico and in vitro methods streamlines the assessment of immunogenicity.
    • This integrated approach significantly reduces the time and financial resources required for drug development and safety assessment.